Ramizes (ramipril) tablets 2.5 mg. №30

$14.00

Manufacturer: Ukraine

Ramizes tablets are a drug that has an antihypertensive effect, helps to lower blood pressure, and dilate blood vessels, and slows the progression of renal failure. Improves the condition of patients after myocardial infarction and the risk of disease progression, reduces cardiac mortality.

Category:

Description

Ramizes (ramipril) tablets 2.5 mg. №30

Composition 

active ingredient: ramipril;

1 tablet contains ramipril 2.5 mg or 5 mg or 10 mg;

Excipients:

  • 2.5 mg tablets: sodium bicarbonate, lactose monohydrate, sodium croscarmellose, pregelatinized starch 1500, magnesium stearate, iron oxide yellow (E 172);
  • 5 mg tablets: sodium bicarbonate, lactose monohydrate, sodium croscarmellose, pregelatinized starch 1500, magnesium stearate, iron oxide yellow (E 172), iron oxide red (E 172);
  • 10 mg tablets: sodium bicarbonate, lactose monohydrate, croscarmellose sodium, pregelatinized starch 1500, magnesium stearate.

Dosage form

Tablets.

Basic physical and chemical properties:

  • 2.5 mg tablets: flat-cylindrical tablets, light yellow in color with a chamfer and a notch, with a weak specific odor or odorless. Minor inclusions and marbling are allowed on the surface of the tablets;
  • 5 mg tablets: flat-cylindrical tablets, light pink in color with a chamfer and a notch, with a weak specific odor or odorless. Minor inclusions and marbling are allowed on the surface of the tablets;
  • 10 mg tablets: flat-cylindrical tablets, white or almost white, with a bevel and a notch, with a slight specific odor or odorless. Slight marbling is allowed on the surface of the tablets.

Pharmacological group

Angiotensin-converting enzyme (ACE) inhibitors, monocomponent. Ramipril.
ATX code C09A A05.

Pharmacological properties

Ramizes tablets 2.5 mg are a drug that has an antihypertensive effect, helps to lower blood pressure, and dilate blood vessels, and slows the progression of renal failure. Improves the condition of patients after myocardial infarction and the risk of disease progression, reduces cardiac mortality.

Indications for use

Ramizes tablets 2.5 mg is prescribed for the treatment of arterial hypertension, heart failure, postinfarction myocardial dysfunction, diabetic and nondiabetic nephropathy, and for the prevention of cardiovascular diseases.

Contraindications

Ramizes tablets 2.5 mg are contraindicated for: renal stenosis, liver failure, arterial hypotension, angioedema, hemodynamically unstable conditions, diabetes mellitus and concomitant treatment with drugs that contain aliskiren and extracorporeal methods, including dialysis or hemofiltration. Also, with personal intolerance to the constituent components and under the age of 18.

Application during pregnancy and lactation

The drug should not be used by women who are planning to have a baby, as well as pregnant and breastfeeding women.

Method of administration and dosage

The drug with arterial hypertension is prescribed at 2.5 mg of ramipril per day, if necessary, then within 15-30 days the dose is increased until the maximum permissible dose of 10 mg per day is reached. If after taking the pills there is a significant decrease in blood pressure, then it is worth starting therapy with 1.25 mg.

  • Patients suffering from heart failure begin treatment with 1.25 mg per day, every 1-2 weeks the dose can be doubled to the maximum daily dose of 10 mg.
  • Patients who need to take pills to prevent cardiovascular diseases begin treatment with 2.5 mg per day, the dose can be increased within 1-2 weeks, and then after 2-3 weeks it can be increased to the maximum daily dose of 10 mg.
  • For patients who have suffered myocardial infarction, the initial dose is 2.5 mg in the morning and in the evening (twice a day). If you need therapy, you can start with 1.25 mg twice a day in the first 2 days after a heart attack. And only after that, the dose can be increased every 1-3 days, doubling it to a maximum daily dose of 10 mg.
  • Patients who have kidney disease, provided that creatinine clearance is from 10 to 60 ml / min, take 1.25 mg per day. The maximum permissible daily dose for such patients is 5 mg. In the case when creatinine clearance is from <60 ml / min, take 2.5 mg per day. The maximum permissible daily dose for such patients is 10 mg.
  • For patients in old age, the minimum initial dose is 1.25 mg; in the future, dose titration should be carried out more gradually.
  • Patients with diabetic and non-diabetic nephropathy should begin therapy with 1.25 mg ramipril per day in the morning. Then the dose can be increased every 2 weeks up to a maximum daily dose of 5 mg.
  • For patients with impaired liver function, the maximum daily dose is 2.5 mg, treatment should be carried out under the strict supervision of a physician.
  • In cases where the patient takes diuretics, it is necessary to stop taking diuretics or reduce the dose before starting treatment. The doctor selects and changes the dose for each patient individually. If diuretics are needed, then treatment begins with a dose of 1.25 mg, while monitoring kidney function and blood potassium levels. The dose adjustment depends on the blood pressure level.
  • Patients with diabetes and with at least one cardiovascular risk factor begin treatment with 2.5 mg per day, the dose can be increased within 1-2 weeks, and then after 2-3 weeks it can be increased to the maximum daily dose of 10 mg.

The drug is taken orally, without chewing, drinking plenty of water, Ramizes can be used before and after meals, as well as during meals.

Overdose

In case of an overdose with Ramizes tablets, the following are possible: arterial hypotension, bradycardia, shock, electrolyte imbalance, and renal failure. In case of intoxication with the drug, the patient needs to do a gastric lavage, take adsorbents to cleanse the body, take measures to restore stable hemodynamics. Provide symptomatic therapy and maintenance.

Side effects

When taking Ramizes tablets, side reactions may occur: myocardial ischemia, peripheral edema, tachycardia, arterial hypotension, arrhythmia, decreased blood pressure, a feeling of increased heart rate, fainting, hypoperfusion, Raynaud’s phenomenon, vasculitis, increased urination, vascular stenosis, impaired renal function, increased urea and creatinine levels, cough, sinusitis, nasal congestion, discomfort and pain in the stomach, bronchitis, indigestion, shortness of breath, dyspepsia, bronchospasm, diarrhea, dry mouth, pancreatitis, vomiting, angioedema, nausea, gastritis, constipation, gloss cholestatic jaundice, stomatitis, hepatitis, liver failure.

Also possible: headache, paresthesia, dizziness, ageusia, tremor, dysgeusia, imbalance, visual impairment, impaired psychomotor functions, hearing impairment, burning sensation, cerebral ischemia, parosmia, conjunctivitis, toxic epidermal necrolysis, tinnitus, rash, hyperhidrosis, pruritus, exfoliative dermatitis, urticaria, onycholysis, dermatitis, photosensitivity reaction, erythema multiforme, pemphigus, Stevens Johnson syndrome, alopecia.

The use of the drug can cause muscle spasms, an increase in the level of potassium in the blood, myalgia, anorexia, loss of appetite, arthralgia, pancytopenia, a decrease in the level of sodium in the blood, eosinophilia, a decrease in the level of hemoglobin, a decrease in the number of leukocytes, erythrocytes, platelets, hemolytic anemia, decreased libido, decreased mood, gynecomastia, anxiety, anxiety, pyrexia, nervousness, sleep disturbances, confusion, drowsiness, asthenia, fatigue.